{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:03:50Z","timestamp":1790795030881,"version":"4.1.0"},"reference-count":21,"publisher":"Japanese Society of Internal Medicine","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,8,15]]},"DOI":"10.2169\/internalmedicine.4398-19","type":"journal-article","created":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T22:07:49Z","timestamp":1590185269000},"page":"1931-1937","source":"Crossref","is-referenced-by-count":46,"title":["SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology"],"prefix":"10.2169","volume":"59","author":[{"given":"Norio","family":"Akuta","sequence":"first","affiliation":[{"name":"Department of Hepatology, Toranomon Hospital and Okinaka Memorial Institute for Medical Research, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kawamura","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Toranomon Hospital and Okinaka Memorial Institute for Medical Research, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichiro","family":"Fujiyama","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Toranomon Hospital and Okinaka Memorial Institute for Medical Research, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Sezaki","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Toranomon Hospital and Okinaka Memorial Institute for Medical Research, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Hosaka","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Toranomon Hospital and Okinaka Memorial Institute for Medical Research, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Toranomon Hospital and Okinaka Memorial Institute for Medical Research, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Liver Research Laboratory, Toranomon Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Saitoh","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Toranomon Hospital and Okinaka Memorial Institute for Medical Research, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitaka","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Toranomon Hospital and Okinaka Memorial Institute for Medical Research, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Toranomon Hospital and Okinaka Memorial Institute for Medical Research, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuji","family":"Arase","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Toranomon Hospital and Okinaka Memorial Institute for Medical Research, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Toranomon Hospital and Okinaka Memorial Institute for Medical Research, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromitsu","family":"Kumada","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Toranomon Hospital and Okinaka Memorial Institute for Medical Research, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 346: 1221-1231, 2002.","DOI":"10.1056\/NEJMra011775"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Williams R. Global changes in liver disease. Hepatology 44: 521-526, 2006.","DOI":"10.1002\/hep.21347"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. World J Gastroenterol 20: 475-485, 2014.","DOI":"10.3748\/wjg.v20.i2.475"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Akuta N, Kawamura Y, Arase Y, et al. Hepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan. BMC Gastroenterol 18: 165, 2018.","DOI":"10.1186\/s12876-018-0900-1"},{"key":"5","unstructured":"5. Kleiner DE, Brunt EM. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis 32: 3-13, 2012."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373: 2117-2128, 2015.","DOI":"10.1056\/NEJMoa1504720"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377: 644-657, 2017.","DOI":"10.1056\/NEJMoa1611925"},{"key":"8","unstructured":"8. Akuta N, Watanabe C, Kawamura Y, et al. Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: preliminary prospective study based on serial liver biopsies. Hepatol Commun 1: 46-52, 2017."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Akuta N, Kawamura Y, Watanabe C, et al. Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus. Hepatol Res 49: 531-539, 2019.","DOI":"10.1111\/hepr.13304"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Lai LL, Vethakkan SR, Nik Mustapha NR, et al. Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus. Dig Dis Sci 65: 623-631, 2020.","DOI":"10.1007\/s10620-019-5477-1"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313-1321, 2005.","DOI":"10.1002\/hep.20701"},{"key":"12","unstructured":"12. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94: 2467-2474, 1999."},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Bedossa P. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology 60: 565-575, 2014.","DOI":"10.1002\/hep.27173"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology 43: 1317-1325, 2006.","DOI":"10.1002\/hep.21178"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382: 941-950, 2013.","DOI":"10.1016\/S0140-6736(13)60683-2"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Ferrannini G, Hach T, Crowe S, et al. Energy balance after sodium-glucose cotransporter 2 inhibition. Diabetes Care 38: 1730-1735, 2015.","DOI":"10.2337\/dc15-0355"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Sorrentino P, Terracciano L, D'Angelo S, et al. Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin, HOMA-IR, and hypertension. Am J Gastroenterol 105: 336-344, 2010.","DOI":"10.1038\/ajg.2009.587"},{"key":"18","unstructured":"18. Fujii H, Imajo K, Yoneda M, et al. HOMA-IR: an independent predictor of advanced liver fibrosis in nondiabetic non-alcoholic fatty liver disease. J Gastroenterol Hepatol 34: 1390-1395, 2019."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Akuta N, Kawamura Y, Arase Y, et al. Circulating microRNA-122 and fibrosis stage predict mortality of Japanese patients with histopathologically confirmed NAFLD. Hepatol Commun 4: 66-76, 2019.","DOI":"10.1002\/hep4.1445"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362: 1675-1685, 2010.","DOI":"10.1056\/NEJMoa0907929"},{"key":"21","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"21. Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387: 679-690, 2016.","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/16\/59_4398-19\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T03:19:39Z","timestamp":1597461579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/16\/59_4398-19\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,15]]},"references-count":21,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4398-19","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,15]]}}}